Showing results (61-70 of 660) with videos related to
Sort By:
Pageof 66
Obstetrics and Gynecology|December 10, 2003
Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapyBruce Ettinger, Deborah Grady, Anna N A Tosteson, et al.Obstetrics and Gynecology|December 10, 2003
Predictors of difficulty when discontinuing postmenopausal hormone therapyDeborah Grady, Bruce Ettinger, Anna N A Tosteson, et al.Journal of Women'S Health (2002)|May 27, 2005
Raloxifene and colorectal cancerJudith M E Walsh, Angela M Cheung, Donald Yang, et al.BJU International|October 18, 2011
Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?Sanoj Punnen, Matthew R Cooperberg, Natalia Sadetsky, et al.Substance Abuse|February 6, 2016
Predictors of higher-risk chronic opioid prescriptions in an academic primary care settingScott R Bauer, Lily Hitchner, Hannah Harrison, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Androgen deprivation therapy and cardiovascular riskSanoj Punnen, Matthew R Cooperberg, Natalia Sadetsky, et al.Menopause (New York, N.Y.)|February 8, 2017
Cardiac autonomic function and hot flashes among perimenopausal and postmenopausal womenCarolyn J Gibson, Wendy Berry Mendes, Michael Schembri, et al.Obstetrics and Gynecology|April 3, 2007
Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trialDeborah Grady, Beth Cohen, Jeffrey Tice, et al.The American Journal of Medicine|June 23, 2009
Raloxifene and risk for stroke based on the framingham stroke risk scoreElizabeth Barrett-Connor, David A Cox, Jingli Song, et al.Menopause (New York, N.Y.)|April 12, 2006
Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 yearsSusan Diem, Deborah Grady, Judy Quan, et al.Pageof 66